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Abstract
The relationship between platelet count and risk of major bleeding in patients with venous
thromboembolism (VTE) during anticoagulation remains unclear. We therefore investigated the
association between platelet count, measured at VTE diagnosis and before the thrombotic
event, and risk of major bleeding. Participants comprised 744 patients with incident VTE
derived from the Tromsø Study. Major bleedings were recorded during the first year after
VTE. Cox-regression was used to calculate hazard ratios (HRs) for major bleeding across platelet
count quartiles.
There were 55 major bleedings (incidence rate 9.1/100 person-years, 95% confidence interval
[CI] 7.0–11.8). The major bleeding risk increased across quartiles of platelet count measured at
VTE diagnosis (P for trend<0.02). In the age- and sex-adjusted model, subjects with platelet
count in the highest quartile (≥300x109/L) had a 4.3-fold (95% CI 1.7–10.9) higher risk of major
bleeding compared to those with platelet count in the lowest quartile (≤192x109/L), and
exclusion of patients with cancer yielded similar results. When platelet count was measured
on average 7 years before a VTE, the corresponding HR was 2.5 (95% CI 0.9–6.7). Our results
suggest that increasing platelet count, assessed several years before and at VTE diagnosis, is
associated with a higher risk of major bleeding, and could be a stable individual marker of
major bleeding risk in VTE-patients.
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Introduction
Major bleeding events are feared and severe complications of
anticoagulant therapy associated with high costs, morbidity
and mortality in the treatment of venous thromboembolism
(VTE) [1–4]. Depending on type, intensity and duration of
anticoagulation, major bleeding has been reported to occur
annually in 3 to 9 per 100 person-years in non-interventional
studies of VTE patients [5–7]. The assessment of major
bleeding risk is essential to guide decisions regarding treat-
ment duration in unprovoked VTE [3]. Furthermore, an accu-
rate risk stratification of major bleeding may identify patients
at high risk of bleeding, who would benefit from targeted
preventive measures during the initial period of anticoagulant
treatment. Known risk factors for major bleeding are predo-
minantly of clinical nature, such as advanced age, active
cancer and co-morbidities, which display only modest discri-
minatory ability when combined in risk assessment models
for major bleeding risk [8–10]. The addition of biomarkers to
clinical risk factors and age improved prediction of major
bleeding in patients with atrial fibrillation in the ABC-model
[11]. Therefore, biomarkers could be promising candidates to
improve discrimination between those at high and low risk of
major bleeding during anticoagulant treatment in VTE.
Platelets are potential attractive biomarkers for bleeding given
their crucial role in hemostasis [12], and the fact that measure-
ment of platelet count is inexpensive and easily obtainable.
However, the relationship between platelet count and risk of
major bleeding in VTE patients remains unclear. For instance,
previous data have shown that both low and high platelet counts
were associated with increased risk of major bleeding in VTE
patients [13,14]. Elucidating the role of platelet count in the risk
of major bleeding may be challenging, as several conditions
associated with VTE can affect platelet count but also increase
the bleeding risk during anticoagulation, such as cancer, liver
disease, major surgery, and trauma [3,15–18]. It is noteworthy
that even though environmental factors influence platelet count,
genetics largely contribute to variation in platelet-related pheno-
types [19]. Indeed, family and twin studies indicate a high herit-
ability of platelet count and indices related to platelet size,
including mean platelet volume (MPV) [19–21]. Moreover, the
intra-individual variation in platelet count has been shown to be
substantially less than the inter-individual variation in healthy
subjects [22]. In light of available data, platelet count appears to
be a stable phenotype within an individual over time.
As a potentially stable phenotype, an individual’s platelet
count could influence the predisposition to bleeding during expo-
sure to anticoagulant therapy. In order to clarify the association of
platelet count with risk of major bleeding in VTE patients under
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anticoagulant treatment, we hypothesized that platelet count mea-
sured at the time of VTE diagnosis and several years before the
thrombotic event were both associated with major bleeding. To
address our study hypothesis, we investigated the association
between platelet count, measured at VTE diagnosis, and risk of
major bleeding during the first year after an incident VTE. Then,
using the same study population, we explored whether platelet
count assessed several years prior to the incident VTE was asso-
ciated with major bleeding.
Methods
Study Population
Study participants originated from the fourth (1994–95), fifth
(2001–02) and sixth (2007–08) surveys of the Tromsø study,
a single-center, population-based cohort in Tromsø, Norway
[23]. Members of the population living in the municipality of
Tromsø were invited to participate in the surveys, and altogether
30 371 unique individuals aged 25–97 years participated.
Identification and subsequent adjudication of potential VTE
cases from the source population have been previously described
in detail [24]. In short, potential VTE cases were identified by
searching the hospital discharge diagnosis registry, the autopsy
registry, and the radiology procedure registry at the University
hospital of North Norway (UNN). Identified cases were adjudi-
cated by trained personnel and only included when signs and
symptoms of deep vein thrombosis (DVT) or pulmonary embo-
lism (PE) were combined with objective confirmation by radiolo-
gical procedures that resulted in a VTE diagnosis requiring
treatment. The study was approved by the Regional Committee
of Research and Medical Health Ethics, and all study participants
provided informed written consent.
From the date of inclusion in one of the three surveys until
December 31 2016, a total of 918 participants developed an
incident VTE (Figure 1). Seventeen participants who died on
the same day of their VTE diagnosis were excluded, leaving
901 eligible study participants. Among these, 29 participants did
Figure 1. Flowchart illustrating the composition of the study population. VTE, venous thromboembolism.
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not have any measurement of platelet count. Of the remaining 872
participants, 17 had missing platelet count values at Tromsø study
enrollment and 111 at VTE diagnosis and were therefore
excluded. The resulting study population consisted of 744 VTE
cases with available platelet count measurement at Tromsø study
enrollment and VTE diagnosis (Figure 1).
Clinical Characteristics of VTE Events
Medical records were searched at time of and 12 weeks preceding
the VTE diagnosis for clinical information on VTE characteristics
and provoking factors. Factors that classified the VTE event as
provoked were major surgery, trauma or acute medical conditions
(acute myocardial infarction, ischemic stroke, or major infectious
disease) within 12 weeks prior to VTE event, marked immobiliza-
tion (confined to bed >3 days, wheel-chair, or long-distance travel
exceeding 4 hours within the last 14 days prior to VTE event), or any
other factor(s) specifically described in the medical records to have
provoked the VTE (e.g. intravascular catheter or plaster cast).
Presence of known active cancer at the time of VTE diagnosis was
regarded as a provoked VTE. In the case of a concurrent DVT and
PE diagnosis, the VTE event was classified as a PE.
The presence of comorbidities, such as hypertension, renal dys-
function, and anemia, was assessed in medical records of VTE
patients. A systolic blood pressure above 160 mmHg defined hyper-
tension. The estimated glomerular filtration rate (eGFR) was calcu-
lated with the chronic kidney disease epidemiology collaboration
equation based on creatinine levels, age, gender and race [25].
Anemia was defined as a hemoglobin level below 11.5 g/dL for
women and below 13.0 g/dL for men at VTE diagnosis. A history of
bleeding was recorded if a previous bleeding event was specifically
noted in the medical records of VTE cases.
To account for type and duration of VTE treatment, we con-
sidered the planned treatment (i.e. heparin, vitamin k antagonist
[VKA] or direct oral anticoagulant) and duration of anticoagula-
tion that were stated by the attending physicians in the medical
records at the time of VTE diagnosis. Duration of anticoagulant
therapy was categorized into 3, 6, 12, and more than 12 months,
as previously described [26].
Platelet Count Measurements
Measurement of platelet-related phenotypes at Tromsø study enroll-
ment, i.e. platelet count and MPV, has previously been described
elsewhere [24]. Briefly, non-fasting blood samples were collected
from an antecubital vein into 5-mL vacutainers containing EDTA as
an anticoagulant (K3- EDTA 40 µL, 0.37 mol/L per tube), and
analyzed within 12 hours in an automated blood cell counter
(Coulter Counter®, Coulter Electronics, Luton, UK). For the platelet
count measurement at VTE diagnosis, we considered the first blood
sample drawn for the diagnostic work-up of VTE, as described in the
medical records of each VTE patient at the UNN. According to the
protocol of the Department of Clinical Chemistry at the UNN, blood
samples were collected in vacutainers containing EDTA.
Major Bleeding Events
The medical records for all study participants were searched for
bleeding events during the 365 days following the VTE at the UNN.
All second-line care and advanced emergency medicine, such as
transfusion of blood products, is exclusively provided by the UNN.
The UNN is situated in the middle of Tromsø municipality, with
a vicinity of approximately 250 km to the nearest hospital providing
comparable health-care functions. Two reviewers (trained medical
personnel from the UNN) adjudicated the bleeding events indepen-
dently in accordance with the criteria proposed by the International
Society on Thrombosis and Hemostasis (ISTH) [27]. In short,
a bleeding event that was fatal, and/or symptomatic in a critical area
or organ, and/or requiring blood transfusion of≥2 units ofwhole blood
or red blood cells or causing a fall in hemoglobin level of≥20 g/L, was
considered major. In case of disagreement, the event was discussed in
an endpoint committee (HSJ and JBH) to reach consensus.
Statistical Analyses
Subjects were followed from the date of their first VTE to the
date of an incident major bleeding, death, migration, or end of
follow-up (i.e. 365 days after the first VTE), whichever came
first. Subjects who died or migrated out of the municipality of
Tromsø were censored at the time of the respective event.
Statistical analyses were performed with STATA version 15.0
MP (Stata Corp. College Station, Texas, United States).
Platelet count was divided into quartiles based on platelet
count distribution measured at VTE diagnosis, and the first quar-
tile was set as the reference. Crude incidence rates (IRs) with 95%
confidence intervals (CIs) of major bleeding were calculated
across quartiles of platelet count and expressed as number of
events per 100 person-years at risk. Cox proportional hazards
regression models were used to estimate hazard ratios (HRs)
with 95% CIs for major bleeding. HRs were adjusted for age
and sex in a first model, with the addition of body mass index
(BMI) and planned duration of anticoagulation therapy to
a second model. Risk estimates were adjusted for treatment dura-
tion because knowledge of platelet count at VTE diagnosis might
have influenced the decision on preplanned treatment length. In
a final fully adjusted model, we included surgery, acute medical
conditions, eGFR, hypertension, history of bleeding and anemia.
The proportional hazards assumption was assessed by evaluating
the parallelism of the log-log survivor function across quartiles of
platelet count, and tested using Schoenfeld residuals. In order to
assess potential non-linearity between platelet count and major
bleeding risk, the association was visualized by a generalized
additive regression plot using R version 3.6.1. Platelet count
was modeled with a smoothing spline fit in a Cox model adjusted
for age, sex, BMI and planned duration of treatment.
The risk of death has been reported to be higher in elderly with
high and low platelet counts compared to those with a normal
platelet count [28]. We therefore additionally performed compet-
ing risk by death analyses and calculated the sub-distribution
hazard ratios (SHRs) to limit overestimation of the relative risk
differences of major bleeding between platelet count categories
[29]. The 1-year cumulative incidences of major bleeding across
platelet count quartiles were visualized in traditional one minus
Kaplan-Meier (1-KM) plots and in cumulative incidence function
plots corrected for competing risk by death.
In addition to possible chemotherapy-induced thrombocytope-
nia, cancer has the potential to induce thrombocytosis [17].
Cancer is also a well-known risk factor for bleeding during antic-
oagulation in VTE [3], and we therefore conducted a sensitivity
analysis excluding all patients with active cancer at VTE diag-
nosis. Using a similar rationale, we stratified analyses according
to provoking status, as cases with provoked VTE are more likely
to be exposed to factors that may affect platelet count and risk of
major bleeding, such as major surgery and trauma [3,18].
Platelet count measured at Tromsø study enrollment was cate-
gorized using the same cutoff values as for platelet count at VTE
diagnosis. HRs for major bleeding were adjusted for age and sex
in a first model, and BMI was added to a second model. It is well
established, and previously shown in the Tromsø study [24], that
platelet count is negatively correlated with MPV, an indice of
platelet size. Platelet size is regarded as a marker of platelet
function, with studies showing that large platelets are more
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reactive and adhere and aggregate faster ex vivo than small plate-
lets [30,31]. Therefore, differences in platelets size could poten-
tially explain the association between platelet count and major
bleeding. In order to investigate the potential of platelet size,
measured as MPV, to mediate the association between platelet
count and major bleeding, we further adjusted HRs for MPV
measured at Tromsø study enrollment.
Results
Baseline characteristics across quartiles of platelet count mea-
sured at VTE diagnosis are presented in Table I. The mean age
and proportion of male subjects decreased across increasing
quartiles of platelet count. Subjects in the highest quartile were
more likely to have anemia, active cancer, provoked VTE, recent
surgery and acute medical conditions compared to those in the
lower quartiles. The planned treatment type and duration of antic-
oagulant therapy did not appear to vary in any consistent manner
across quartiles of platelet count.
Among the 744 patients with incident VTE, there were 55
major bleeding events within 1 year of VTE diagnosis during
605 person-years (IR 9.1 per 100 person-years, 95% CI 7.0–11.8),
with a median time from VTE events to major bleeding of
35 days (interquartile range [IQR] 11–183 days). Major bleeding
characteristics and classification according to ISTH criteria are
presented in Supplemental Table I. Three bleeding events were
fatal (within 1 week), and 40% of the major bleedings were
symptomatic in critical areas or organs.
The crude IRs and relative risks for major bleeding according to
quartiles of platelet count measured at VTE diagnosis are presented
in Table II. IRs for major bleeding increased across quartiles of
platelet count, from 3.8 per 100 person-years (95% CI 1.7–8.6) in
the lowest category (≤192 x109/L) to 12.8 per 100 person-years
(95% CI 8.1–20.3) in the highest category (≥300 x109/L). Likewise,
in the age- and sex-adjusted model, HRs for major bleeding
increased with increasing platelet count in a dose-response fashion.
Compared to the first quartile, HRs for major bleeding were 2.7
(95% CI 1.0–6.9), 3.1 (95% CI 1.2–8.0) and 4.3 (95% CI 1.7–10.9)
for quartiles 2 to 4, respectively. Further adjustment for BMI and
planned duration of anticoagulant treatment yielded essentially simi-
lar results (Table II). With additional adjustments for surgery, acute
medical conditions, eGFR, hypertension, history of bleeding and
anemia, the risk estimates were somewhat attenuated, with an HR of
3.4 (95%CI 1.3–8.8) for the highest vs. the lowest quartile of platelet
count, with virtually no changes in risk estimates after taking the
presence of death as competing event (HR 3.2, 95% CI 1.2–8.6). In
all models of the overall population, there was a trend (P for trend
≤0.02) for increased risk ofmajor bleeding by increasing quartiles of
Table I. Baseline characteristics according to quartiles of platelet count measured at venous thromboembolism diagnosis.
Quartiles of platelet count (109/L)




(n = 174) ≥300 (n = 186)
Age (years), mean±SD 71 ± 12 70 ± 13 70 ± 13 66 ± 14
Sex, males 61 (117) 51 (98) 42 (73) 40 (75)
BMIa (kg/m2), mean±SD 27.2 ± 4.4 27.6 ± 4.3 27.7 ± 4.9 27.2 ± 5.0
Hypertensionb 18 (34) 18 (35) 22 (38) 12 (23)
eGFR (ml/min/1.732), mean±SD 67.1 ± 24.4 70.7 ± 22.8 73.6 ± 23.1 78.6±24.5
Previous stroke 8 (15) 6 (11) 8 (14) 9 (16)
History of bleedingc 4 (8) 6 (11) 4 (7) 9 (17)
Anemiad 36 (69) 26 (49) 29 (51) 47 (87)
Active cancere 26 (49) 19 (36) 21 (37) 31 (57)
VTE characteristics
DVT 55 (106) 58 (111) 62 (108) 56 (105)
PE ± DVT 45 (86) 42 (81) 38 (66) 44 (81)
Unprovoked 47 (91) 44 (85) 47 (82) 33 (61)
Provoked 53 (101) 56 (107) 53 (92) 67 (125)
Trauma 9 (18) 8 (16) 9 (15) 9 (17)
Surgery 10 (20) 12 (23) 16 (28) 21 (39)
Acute medical conditionsf 11 (21) 12 (23) 9 (16) 19 (35)
Immobilizationg 24 (47) 24 (46) 18 (31) 20 (38)
Initial thrombolytic therapy 7 (13) 4 (8) 4 (7) 4 (7)
Planned treatment type
Heparinh 21 (40) 18 (34) 16 (28) 23 (43)
Heparinh and VKA 63 (120) 71 (136) 68 (118) 61 (114)
DOAC 6 (11) 3 (6) 7 (13) 6 (12)
Planned duration of anticoagulation
≤3 months 19 (36) 23 (45) 26 (46) 30 (55)
>3 including 6 months 39 (75) 42 (80) 37 (64) 28 (52)
>6 including 12 months 29 (56) 26 (49) 24 (42) 27 (51)
>12 months 13 (25) 9 (18) 13 (22) 15 (28)
Categorical variables are shown as percentages with numbers in brackets, % (n).
SD, standard deviation; BMI, body mass index; VKA, vitamin K antagonist; DOAC, direct oral anticoagulant; DVT, deep vein thrombosis; PE,
pulmonary embolism; eGFR, estimated glomerular filtration rate.
aBMI was calculated as weight in kilograms divided by the square of height in meters (kg/m2) in the Tromsø study.
bSystolic blood pressure >160 mmHg.
cA history of bleeding was present if a previous bleeding event was specifically noted in the medical records of VTE cases.
dhemoglobin <11.5 g/dL for women and <13.0 g/dL for men.
eActive cancer at the time of VTE diagnosis.
fAcute myocardial infarction, ischemic stroke or major infectious disease within 12 weeks prior to VTE.
gConfined to bed >3 days, wheel-chair, or long-distance travel exceeding 4 hours within the last 14 days prior to VTE event.
hLow molecular weight heparin or unfractionated heparin.
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platelet count. In the sensitivity analysis, the risk estimates were
slightly attenuated after excluding patients with cancer, and the HRs
were 1.9 (95% CI 0.6–5.7), 1.8 (95% CI 0.5–6.1) and 2.9 (95% CI
0.9–9.5) for quartiles 2 to 4, respectively, compared to the first
quartile in the fully adjusted model (Table II). Supplemental
Table II describes the stepwise adjustment for the aforementioned
covariates for the overall population and those without cancer. In
analyses stratified according to planned type of anticoagulant, the
results did not appear to differ substantially between subjects treated
with heparins+VKAs compared to subjects treated with heparins
only, even though therewere relatively few individuals in the heparin
group (Supplemental Table III).
Figure 2a shows the risk of major bleeding as a continuous
function of platelet count. As indicated in the density plot, the
major bleeding risk increased linearly within the 25–75th percentile
range of platelet count (192–299 x 109/L). The 1-year cumulative
incidences of major bleeding across quartiles of platelet count were
estimated by 1-KM (Figure 3a), and by the cumulative incidence
function in the presence of competing risk by death (Figure 3b).
The cumulative incidences of major bleeding increased with
increasing quartiles of platelet count (Figure 3a), and the results
remained essentially similar after taking competing risk by death
into account (Figure 3b). The majority of the major bleeding events
occurred in the first 3 months after the VTE, and the 3-month
cumulative incidences of major bleeding were 1.6%, 4.3%, 5.2%
and 6.2% for quartiles 1–4, respectively (Figure 3b). Of note, in the
six major bleeding events occurring among patients in the lowest
quartile, platelet counts ranged from 123 to 181 x 109/L.
In subgroups (Table III), the HRs for major bleeding in
patients with provoked VTE were similar in quartiles 2–4 com-
pared to the reference, ranging from 3.5 (95% CI 1.0–12.7) to 4.5
(95% CI 1.3–16.0) in the age- and sex-adjusted models. For
unprovoked VTE, subjects with a platelet count in the two highest
quartiles had a 2- to 3-fold higher risk of major bleeding com-
pared to those with a platelet count in the first quartile, but CIs
were wide and included unity.
Table II. The 1-year risk of major bleeding according to quartiles of platelet count measured at venous thromboembolism diagnosis.
Quartiles of
platelet count (109/L) Major bleeding IR (95% CI) HR (95% CI)a HR (95% CI)b HR (95% CI)c SHR (95% CI)c
All VTE patients
≤192 6 3.8 (1.7–8.6) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
193–239 15 9.2 (5.6–15.3) 2.7 (1.0–6.9) 2.7 (1.0–7.0) 2.4 (0.9–6.3) 2.5 (1.0–6.5)
240–299 16 11.0 (6.7–17.9) 3.1 (1.2–8.0) 3.2 (1.2–8.2) 2.8 (1.1–7.4) 3.1 (1.2–8.0)
≥300 18 12.8 (8.1–20.3) 4.3 (1.7–10.9) 4.4 (1.7–11.2) 3.4 (1.3–8.8) 3.2 (1.2–8.6)
p for trend .002 .002 .01 .02
VTE patients without cancer
≤192 5 4.1 (1.7–9.8) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
193–239 9 6.3 (3.3–12.2) 1.9 (0.6–5.6) 2.0 (0.7–5.9) 1.8 (0.6–5.4) 1.9 (0.6–5.7)
240–299 9 7.2 (3.7–13.8) 2.0 (0.7–6.1) 2.1 (0.7–6.4) 1.6 (0.5–5.2) 1.8 (0.5–6.1)
≥300 13 11.6 (6.8–20.0) 4.0 (1.4–11.4) 4.2 (1.5–12.1) 2.8 (0.9–8.5) 2.9 (0.9–9.5)
p for trend .01 .01 .08 .09
IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval; SHR, sub-distribution hazard ratio.
aAdjusted for age and sex.
bAdjusted for age, sex, body mass index and planned duration of anticoagulant therapy.
cAdjusted for age, sex, body mass index, planned duration of anticoagulant therapy, surgery, acute medical conditions (acute myocardial infarction,
ischemic stroke, or major infectious disease), estimated glomerular filtration rate, hypertension (systolic blood pressure >160 mmHg), history of
bleeding (specifically noted in the medical records of VTE cases), and anemia (hemoglobin level below 11.5 g/dL for women and below 13.0 g/dL
for men at VTE diagnosis).
SHR denotes the HR after taking competing risk by death into account.
Figure 2. The risk of major bleeding as a continuous function of platelet count measured at venous thromboembolism diagnosis (a, adjusted for age,
sex, body mass index and planned duration of anticoagulation) and at Tromsø study enrollment (b, adjusted for age, sex and body mass index) in
a generalized additive regression model. The solid line shows hazards ratios, enclosed by shaded areas indicating 95% confidence intervals. The
distribution of platelet count is shown in a density plot at the bottom, and vertical lines indicate quartile cutoffs.
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In our cohort, the median time from blood sampling in
Tromsø 4–6 to VTE diagnosis was 6.8 years (IQR 3.1–9.2).
There was a positive correlation between platelet count assessed
at Tromsø study enrollment and VTE diagnosis (Spearman’s
rho = 0.52, P < .001). Moreover, as expected, platelet count at
Tromsø study enrollment was negatively associated with MPV
(Spearman’s rho = −0.42, P < .001). As described in Table IV,
the risk of major bleeding increased with increasing platelet
count measured several years before the incident VTE. In the
age- and sex adjusted model, subjects in the highest category of
platelet count (i.e. ≥300 x 109/L) had a 2.5-fold (HR 2.5, 95%
0.9–6.7) higher risk of major bleeding after developing a VTE
compared to subjects with a platelet count in the lowest category
(i.e. ≤192 x 109/L). Risk estimates did not materially change
after adjusting for BMI, but were somehow attenuated when
MPV was added to the regression models, mainly for the highest
category of platelet count (HR 2.0, 95% CI 0.7–5.6). When the
risk of major bleeding was visualized as a function of platelet
count measured at Tromsø study enrollment, the association
displayed a pattern similar to the results for platelet count
assessed at VTE diagnosis (Figure 2b).
Discussion
In this study, we found that an increasing platelet count measured
at VTE diagnosis was associated with a higher risk of major
bleeding in a dose-response fashion during the first year after
the VTE. Exclusion of patients with active cancer and subgroup
analyses stratified by provoked and unprovoked VTE yielded
similar results. When platelet count was measured in the same
study participants several years prior to the development of the
incident VTE, an increasing platelet count was also associated
with a higher risk of major bleeding. Our results suggest that
platelet count is a stable phenotype within an individual over time
that may influence the susceptibility to bleeding during antic-
oagulant treatment after a VTE.
In our study of patients derived from the general population,
the overall major bleeding rate of 9.1 per 100 person-years was
considerably higher than the rate of about 1.0 per 100 person-
years found in randomized controlled trials (RCTs) involving
VTE patients [32]. However, unselected patients derived from
the general population have more often serious comorbidities
and are managed under less intensive surveillance as compared
to patients selected into RCTs. In addition, RCTs evaluating the
efficacy and safety of anticoagulants are more likely to exclude
patients with a bleeding predisposition. Notably, 24% of our
patients had active cancer at the time of VTE diagnosis, which
is an established risk factor for bleeding during anticoagulation
[3]. Our rate of major bleeding is in agreement with a prospective
cohort comprising 842 VTE patients treated with anticoagulant
therapy in the community [33]. In this study, the rate of major
bleeding was 10.6 per 100 person-years, and it was particularly
high in analysis restricted to VTE patients with cancer (15.7 per
100 person-year). Another clinically relevant finding in our study
was the fact that the median time from incident VTE to major
bleeding was 35 days, with the majority of the major bleeding
events occurring within the first 3 months after VTE. These
results are consistent with previous data [1] and underscore the
concept that patients with an underlying predisposition to bleed-
ing are more likely to develop a major bleeding shortly after
initiation of anticoagulant therapy.
To the best of our knowledge, we are the first to investigate the
association of platelet count, measured within the same subjects
prior to and at VTE diagnosis, with risk of major bleeding. A few
previous studies have explored the relationship between platelet
count and major bleeding in VTE [13,14,34]. In a study compris-
ing 3012 VTE patients, Yamashita et al. assessed the influence of
platelet count at VTE diagnosis on the risk of major bleeding
[34], and reported a higher risk of major bleeding in patients with
a moderate to severe thrombocytopenia (<100 x 109/L) compared
to those with no thrombocytopenia (>150 x 109/L). Apparently,
these findings are in contrast with our results. However, the study
by Yamashita et al. is not necessarily comparable to the present
study. For example, the platelet count cutoffs were determined
according to clinical preferences in their study (i.e. 100 x 109/L
and 150 x 109/L) and these cutoffs are included within the lowest
quartile in our analyses. Furthermore, the authors did not treat
death as a competing risk in their analyses, which could have led
to an overestimation of the association between thrombocytopenia
and major bleeding. The relationship between platelet count mea-
sured at VTE diagnosis and major bleeding was also investigated
in the RIETE registry [13,14]. Di Micco et al. assessed the three-
month risk of major bleeding in 43078 VTE patients according to
categories of platelet counts ranging from <80 x 109/L to >450
x 109/L [13]. In patients with and without cancer, both the highest
(>450 x 109/L) and lowest (<80 x 109/L) categories were asso-
ciated with increased risk of major bleeding when compared to
a platelet count ranging from 150 to 300 x 109/L [13]. Similar to
our findings, Di Micco et al. found that a high platelet count was
associated with increased risk of major bleeding.
Here we found a dose-response relationship between an
increasing platelet count, assessed at VTE diagnosis, and risk of
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Figure 3. One-year cumulative incidence of major bleeding by quartiles
of platelet count measured at venous thromboembolism diagnosis esti-
mated by 1-Kaplan-Meier (a) and in the presence of death as competing
event (b).
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subgroup analyses were limited due to the lower number of
participants, cancer or other comorbidities with high mortality
rates did not appear to substantially contribute to this relationship,
as risk estimates were only slightly attenuated after excluding
patients with active cancer and when competing risk of death
was taken into account [29]. Other comorbidities or conditions,
including surgery, acute medical conditions (acute myocardial
infarction, ischemic stroke and major infectious disease), hyper-
tension, renal function (i.e. eGFR), history of bleeding and ane-
mia appeared to partially explain the relationship, as adjustment
for these conditions had a marginal impact on the risk estimates,
with an increasing platelet count still being associated with
a higher risk of major bleeding. Moreover, a positive association
between platelet count and major bleeding risk was found not
only in patients with provoked VTE but also in those with unpro-
voked events, albeit less pronounced in the latter group with the
95% CIs of risk estimates including unity. Thus, transient factors
related to provoked VTEs that can induce an increase in platelet
count, like major surgery or trauma [18], did not seem to con-
tribute to a great extent to the relationship between platelet count
and major bleeding.
In the present study, a platelet count measured on average 7 years
prior to the incident VTE still showed a dose-response relationship
with major bleeding in analyses adjusted for age, sex, and BMI,
although the confidence intervals of risk estimates included unity.
When compared to the lowest quartile of platelet count, the highest
quartile was associated with a 2.5-fold (95% CI 0.9–6.8) higher risk
of major bleeding. Furthermore, the platelet count measured at VTE
diagnosis displayed a significant positive correlation with the plate-
let count measured several years before the thrombotic event. Such
findings reinforce the notion that platelet count is a stable phenotype
within an individual over time, as previously demonstrated by others
[20,22]. This notion is consistent with the high degree of heritability
reported for some platelet-related phenotypes, including platelet
count and indices of platelet size, such as MPV [19–21]. In our
study, platelet count and MPV, measured at Tromsø study enroll-
ment, showed a negative moderate correlation, and the impact of
platelet count on major bleeding risk was somehow attenuated after
adjusting for MPV. This finding suggests that differences in platelet
size could partly explain the association between platelet count and
major bleeding. Large and small platelets have been shown to sub-
stantially differ in their functional roles in the hemostatic system.
Table III. The 1-year risk of major bleeding according to quartiles of platelet count measured at venous thromboembolism diagnosis in provoked and
unprovoked cases.
Quartiles of
platelet count (109/L) Major bleeding IR (95% CI) HR (95% CI)a HR (95% CI)b HR (95% CI)c SHR (95% CI)c
Provoked
≤192 3 4.0 (1.3–12.5) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
193–239 13 15.8 (9.2–27.2) 4.1 (1.2–14.4) 4.3 (1.2–15.1) 3.5 (1.0–12.5) 3.8 (1.1–13.6)
240–299 10 14.0 (7.5–25.9) 3.5 (1.0–12.7) 3.7 (1.0–13.6) 3.3 (0.9–12.4) 3.6 (1.0–13.2)
≥300 13 15.4 (8.9–26.5) 4.5 (1.3–16.0) 4.7 (1.3–16.6) 3.7 (1.0–13.5) 3.4 (1.0–12.3)
p for trend .04 .04 .08 .08
Unprovoked
≤192 3 3.7 (1.2–11.4) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
193–239 2 2.5 (0.6–10.0) 0.8 (0.1–4.7) 0.8 (0.1–4.6) 0.7 (0.1–4.5) 0.7 (0.1–4.1)
240–299 6 8.1 (3.6–18.0) 2.4 (0.6–10.1) 2.3 (0.6–9.9) 1.7 (0.4–7.6) 1.8 (0.3–9.9)
≥300 5 8.9 (3.7–21.4) 3.3 (0.8–14.4) 3.3 (0.8–14.6) 2.7 (0.6–12.4) 2.7 (0.5–13.7)
p for trend .05 .05 0.1 0.2
IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval; SHR, sub-distribution hazard ratio.
aAdjusted for age and sex.
bAdjusted for age, sex, body mass index and planned duration of anticoagulant therapy.
cAdjusted for age, sex, body mass index, planned duration of anticoagulant therapy, estimated glomerular filtration rate, hypertension (systolic blood
pressure >160 mmHg), history of bleeding (specifically noted in the medical records of VTE cases), and anemia (hemoglobin level below 11.5 g/dL
for women and below 13.0 g/dL for men at VTE diagnosis)
SHR denotes the HR after taking competing risk by death into account.
Table IV. The 1-year risk of major bleeding in patients with venous thromboembolism according to platelet count measured at Tromsø study
enrollment.
Categories of
platelet count (109/L) Major bleeding IR (95% CI) HR (95% CI)a HR (95% CI)b HR (95% CI)c SHR (95% CI)c
≤192 6 6.0 (2.7–13.3) 1 (reference) 1 (reference) 1 (reference) 1 (reference)
193–239 18 9.3 (5.9–14.8) 1.7 (0.7–4.2) 1.7 (0.7–4.2) 1.6 (0.6–4.0) 1.5 (0.6–3.8)
240–299 19 9.7 (6.2–15.2) 1.9 (0.8–4.9) 1.9 (0.8–4.9) 1.7 (0.6–4.4) 1.6 (0.6–4.1)
≥300 12 10.5 (5.9–18.4) 2.5 (0.9–6.7) 2.5 (0.9–6.8) 2.0 (0.7–5.6) 1.9 (0.6–5.5)
p for trend .08 .07 .2 .3
IR, incidence rate per 100 person-years; HR, hazard ratio; CI, confidence interval; SHR, sub-distribution hazard ratio.
aAdjusted for age and sex.
bAdjusted for age, sex and body mass index.
cAdjusted for age, sex, body mass index and mean platelet volume.
Categories of platelet count measured at Tromsø study enrollment were established using the same cutoff points of platelet count assessed at VTE
diagnosis.
SHR denotes the HR after taking competing risk by death into account.
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Compared to small platelets, large platelets are associated with
increased reactivity, shortened bleeding time, faster adhesion to
collagen and aggregation ex vivo, and increased expression of gly-
coproteins on their membranes [30,31]. Reticulated platelets, which
are large and hyperreactive platelets, display a prothrombotic profile,
as recently revealed in transcriptome analysis [35].Moreover, results
from epidemiological studies, including the Tromsø Study, show
that an increased MPV is associated with a higher risk of arterial
cardiovascular disease [36] and VTE [24], thereby supporting the
higher prothrombotic potential of large platelets [24]. It is of interest
that in the presence of substantial thrombocytopenia (<20 x 109/L),
a low MPV has been shown to be a stronger predictor of bleeding
than platelet count [37]. In light of these data, we can speculate that
an increasing platelet count, even within a normal range, would be
associated with a lower platelet reactivity, as reflected by a decrease
in MPV, which could predispose to major bleeding during antic-
oagulant treatment after a VTE.
Platelet count, as a phenotype that is stable over time within
an individual, seems a promising biomarker to improve stratifi-
cation of major bleeding risk during anticoagulant treatment.
However, the use of platelet count in risk assessment models in
patients with VTE and atrial fibrillation has yielded controversial
results, with studies using different cutoff values of platelet count
[38–40]. Whether an elevated platelet count at the appropriate
cutoff value can improve discrimination of VTE patients with
high and low risk of major bleeding would require further
investigation.
The inclusion of subjects derived from the general popula-
tion, the complete and validated registry of VTE events, and the
strict criteria used to define major bleeding based on the ISTH
recommendations are among the main strengths of the present
study. Additionally, the exclusivity of UNN as the sole health-
care provider enhances the probability to capture all relevant
major bleeding events. The study also has some limitations.
There were 157 subjects (17% of eligible participants) with
missing values on platelet count who were excluded from our
analyses (Figure 1). However, there were no substantial differ-
ences in the baseline characteristics among subjects with and
without missing values of platelet count (data not shown), indi-
cating that missing values was presumably at random. The num-
ber of major bleeding events was low in some subgroups, which
could have resulted in limited statistical power. Our results
should therefore be interpreted with caution, especially in sub-
group analysis. Only a few patients (15 out of 744 subjects
included in the analyses) had a platelet count <100 x 109/L at
the time of VTE diagnosis. Therefore, we were not able to
evaluate the role of moderate to severe thrombocytopenia on
the risk of major bleeding. It is noteworthy that the association
between platelet count and major bleeding was less pronounced
when platelet count was measured at Tromsø study enrollment as
compared to the assessment at VTE diagnosis. Even though
platelet count is subject to less intra-individual compared to
inter-individual variability [22], individual changes due to
advancing age or environmental factors (such as onset of dis-
eases) may occur over time [18,41]. In our cohort study, with
a long period of follow-up, values of platelet count might have
changed over time in participants with or without a major bleed-
ing event. This could have led to an underestimation of the
association between platelet count measured at Tromsø study
enrollment and major bleeding, due to regression dilution bias,
a phenomenon that occurs in the long-term follow-up of cohort
studies [42]. Unfortunately, we did not have information on
concomitant use of drugs that might have affected the bleeding
risk, such as antiplatelet agents. However, we conducted
a sensitivity analysis excluding VTE cases with a known medical
history of myocardial infarction or stroke (n = 131), as these
would be the most likely users of antiplatelet medication
(Supplemental Table IV). The association between an increasing
platelet count and major bleeding remained, albeit somewhat
attenuated compared to the main analyses, suggesting that the
association was not primarily driven by antiplatelet medications.
Finally, MPV is not commonly part of the diagnostic work-up for
subjects with suspected acute VTE, and information on MPV at
VTE diagnosis was therefore not available.
In conclusion, our results suggest that an increasing platelet
count, measured several years before and at VTE diagnosis, is
associated with a higher risk of major bleeding during the
first year after an incident VTE. Our findings imply that
a platelet count measured at VTE diagnosis is a stable phenotype
within an individual over time that has the potential to improve
risk stratification of major bleeding after a VTE.
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